3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Dermatologic
1
Conditions
Keratosis, Actinic
5
Uterine Cervical Neoplasms
3
Uterine Cervical Dysplasia
2
Papillomavirus Infections
2
Melanoma
2
Hemangioma, Capillary
2
Breast Neoplasms
2
Vulvar Neoplasms
1
Vulvar High Grade Squamous Intraepithelial Lesion (HSIL)
1
Virus Diseases
1
Vaginal Neoplasms
1
Urinary Bladder Neoplasms
1
Skin Neoplasms
1
Sexually Transmitted Diseases
1
Precancerous Conditions
1
Pigmentation Disorders
1
Ovarian Neoplasms
1
Non-Muscle Invasive Bladder Neoplasms
1
Neoplasms
1
Neoplasm Metastasis
1
Lung Neoplasms
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Hemangioma
1
HPV
1
Fallopian Tube Neoplasms
1
Endometrial Neoplasms
1
Condylomata Acuminata
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Basal Cell
1
Carcinoma in Situ
1
Interventions
aldesleukin
16
Cyclophosphamide
14
fludarabine phosphate
11
Interleukin-2
11
fludarabine
10
Nivolumab
7
pembrolizumab
5
cemiplimab
5
Ipilimumab
5
Temozolomide
4
Fluorouracil
4
Aminolevulinic Acid
4
sonidegib
3
Surgical Procedures, Operative
3
Radiotherapy
3
zanolimumab
2
trametinib
2
talabostat
2
montanide ISA 51
2
dabrafenib
2
Whole-Body Irradiation
2
Tablets
2
Semaxinib
2
Radiation
2
Petrolatum
2
Peptides
2
MART-1 Antigen
2
Gefitinib
2
Eflornithine
2
Cisplatin
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Skin Neoplasms
×
Imiquimod
×
Clear all
NCT03534947
2025-12-16
SONIB
Melanoma Institute Australia
Phase 2
Completed
16 enrolled